These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9663925)

  • 21. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
    Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
    Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kidney is an important target for the antihypertensive action of an angiotensin II receptor antagonist in spontaneously hypertensive rats.
    Wood JM; Schnell CR; Levens NR
    Hypertension; 1993 Jun; 21(6 Pt 2):1056-61. PubMed ID: 8505092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study].
    Skvortsov AA; Nasonova SN; Sychev AV; Orlova IaA; Baklanova NA; Masenko VP; Mareev VIu; Belenkov IuN
    Kardiologiia; 2006; 46(7):33-51. PubMed ID: 16883264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
    Davis BJ; Cao Z; de Gasparo M; Kawachi H; Cooper ME; Allen TJ
    J Hypertens; 2003 Jan; 21(1):209-16. PubMed ID: 12544453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
    Yamamoto S; Hayashi N; Kometani M; Nakao K; Inukai T
    Arzneimittelforschung; 1997 May; 47(5):604-12. PubMed ID: 9205773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular status following combined angiotensin-converting enzyme and AT1 receptor inhibition in conscious spontaneously hypertensive rats.
    Duke LM; Paull JR; Widdop RE
    Clin Exp Pharmacol Physiol; 2003; 30(5-6):317-23. PubMed ID: 12859420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns.
    Krombach RS; Clair MJ; Hendrick JW; Houck WV; Zellner JL; Kribbs SB; Whitebread S; Mukherjee R; de Gasparo M; Spinale FG
    Cardiovasc Res; 1998 Jun; 38(3):631-45. PubMed ID: 9747431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hemodynamic and biochemical consequences.
    Bunkenburg B; Schnell C; Baum HP; Cumin F; Wood JM
    Hypertension; 1991 Sep; 18(3):278-88. PubMed ID: 1889842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP.
    Siragy HM; de Gasparo M; El-Kersh M; Carey RM
    Hypertension; 2001 Aug; 38(2):183-6. PubMed ID: 11509473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
    Moniwa N; Varagic J; Ahmad S; VonCannon JL; Ferrario CM
    Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):15-29. PubMed ID: 22222314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood pressure variability, impaired autonomic function and vascular senescence in aged spontaneously hypertensive rats are ameliorated by angiotensin blockade.
    Sueta D; Koibuchi N; Hasegawa Y; Toyama K; Uekawa K; Katayama T; Ma M; Nakagawa T; Waki H; Maeda M; Ogawa H; Kim-Mitsuyama S
    Atherosclerosis; 2014 Sep; 236(1):101-7. PubMed ID: 25016364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats.
    Tschudi MR; Criscione L; Novosel D; Pfeiffer K; Lüscher TF
    Circulation; 1994 May; 89(5):2212-8. PubMed ID: 8181147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
    Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
    Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress.
    Yagi S; Morita T; Katayama S
    Hypertens Res; 2004 Feb; 27(2):129-35. PubMed ID: 15005276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition.
    Mahmud A; Feely J
    Am J Hypertens; 2002 Apr; 15(4 Pt 1):321-5. PubMed ID: 11991217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
    Spinale FG; Mukherjee R; Iannini JP; Whitebread S; Hebbar L; Clair MJ; Melton DM; Cox MH; Thomas PB; de Gasparo M
    Circulation; 1997 Oct; 96(7):2397-406. PubMed ID: 9337216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
    Kometani M; Hayashi N; Yamamoto S; Nakao K; Inukai T
    Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
    van Esch JH; Moltzer E; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
    J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
    Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
    J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.